[EN] ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF [FR] ACTIVATEURS DE LA VOIE DU GÈNE INDUCTIBLE PAR L'ACIDE RÉTINOÏQUE "RIG-I" ET LEURS PROCÉDÉS D'UTILISATION
ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF
申请人:Kineta Immuno-Oncology LLC
公开号:US20200055871A1
公开(公告)日:2020-02-20
The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.
本发明涉及式(I)化合物,该化合物是RIG-I通路的激活剂。
Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors
作者:Li Liu、Manshu Tang、Rajan Pragani、Frank G. Whitby、Ya-qin Zhang、Bijina Balakrishnan、Yuhong Fang、Surendra Karavadhi、Dingyin Tao、Christopher A. LeClair、Matthew D. Hall、Juan J. Marugan、Matthew Boxer、Min Shen、Christopher P. Hill、Kent Lai、Samarjit Patnaik
DOI:10.1021/acs.jmedchem.1c00945
日期:2021.9.23
2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site
作者:Kevin D. Rynearson、Brian Charrette、Christopher Gabriel、Jesus Moreno、Mark A. Boerneke、Sergey M. Dibrov、Thomas Hermann
DOI:10.1016/j.bmcl.2014.05.088
日期:2014.8
2-Aminobenzoxazoles have been synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The compounds were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors. Structure-activity relationships in the target binding of substituted benzoxazole ligands were investigated. (C) 2014 Elsevier Ltd. All rights reserved.
Palazzo; Tornetta, Bollettino delle Sedute della Accademia Gioenia di Scienze Naturali in Catania, 1957, vol. <4> 4, p. 205,213
作者:Palazzo、Tornetta
DOI:——
日期:——
[EN] ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF<br/>[FR] ACTIVATEURS DE LA VOIE DU GÈNE INDUCTIBLE PAR L'ACIDE RÉTINOÏQUE "RIG-I" ET LEURS PROCÉDÉS D'UTILISATION
申请人:KINETA INC
公开号:WO2020036812A1
公开(公告)日:2020-02-20
The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.